All News

virus,injection,COVID,vaccine

Two Week Methotrexate Hold with COVID-19 Vaccination

Jack Cush, MD

A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal. 

Read Article
hudsonpsoriasis.jpg

Bimekizumab Safety in Psoriasis Patients

Jack Cush, MD

A pooled analyses of data from eight, phase 2 and 3 randomized clinical trials shows bimekizumab, a dual IL-17A/F inhibitor, to be effective in plaque psoriasis and was well tolerated aside from an increased incidence of mild to moderate oral candidiasis. 

Read Article
Distance

PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals?

Rachel Tate, DO

POS0309 at EULAR 2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies. 

Read Article
guidelines.recommendations.jpg

BSR Guideline for Psoriatic Arthritis - 2022 Update

Jack Cush, MD

The British Society of Rheumatology has published their updated 2022 recommendations for the use of biologics and targeted synthetic treatments in patients with psoriatic arthritis. These guidelines follow initial treatment with a single conventional systemic disease-modifying anti-rheumatic drug, typically methotrexate typically. They noted that up to 50% of people with PsA require biologic or targeted synthetic (b/ts)DMARD therapy. 

Read Article
exhibitor.floor.ACR

EULAR 2022 – Day 4 Report

Jack Cush, MD

Bags are packed, ready to go, but wait there’s more abstracts to show.



The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased. 

Read Article
PSA2L.jpg

Key Psoriatic Arthritis topics and updates at EULAR 2022

Antoni Chan, MD, PhD

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  Here are my top picks from this year's meeting.

Read Article
RWE & Registries in Psoriatic Arthritis Dr. Alexis Ogdie presents RWE & Registries in Psoriatic Arthritis at the 2022 RheumNow Live meeting. https://t.co/zYcDrhgbNr https://t.co/s4Hv3ub9Av

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj

Links:

Dr. John Cush RheumNow ( View Tweet)
Studies suggest that the IL-23/Th-17 axis is one of the key pathways involved in the pathogenesis of plaque psoriasis and psoriatic arthritis. Learn more here: https://t.co/oj00pk4dLT Sponsored by Janssen @JanssenUS https://t.co/4IhyX6sF7p

Links:

Dr. John Cush RheumNow ( View Tweet)
Miss this week's TNR? Watch the playback. https://t.co/LSlw939Vj2 https://t.co/K62afKWz95

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA UPLIFT survey: do rheumatologists and patients agree on treatment goals? POS0309 at #EULAR2022 highlighted both similarities and differences between our patients and ourselves when it comes to PsA disease and treatment strategies. https://t.co/8newrxP1hn https://t.co/c9SwrRd8mw

Links:

Dr. John Cush RheumNow ( View Tweet)
As #EULAR2022 comes to an end, there is still the playback that I am looking forward to watch. Here are my key Psoriatic Arthritis topics and updates from EULAR 2022 https://t.co/KNGGUJuukg @RheumNow

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)

In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
Dr. Antoni Chan synovialjoints ( View Tweet)
Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi
Robert B Chao, MD doctorRBC ( View Tweet)
Kohm et al. Efficacy of IL12/23i ustekinumab independent of MTX in PsA. No additive benefit of MTX on joint, skin, QoL, function @RheumNow #EULAR2022 POS1059

Richard Conway RichardPAConway ( View Tweet)

Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU
TheDaoIndex KDAO2011 ( View Tweet)
McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB

Links:

Richard Conway RichardPAConway ( View Tweet)
Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% vs 7%,PASI90 69% vs 7%, ACR20 67% vs 16%, ACR70 27% vs 0.8%, PASI 100 60% vs 5%, MDA 44% vs 6%, no new safety signals #EULAR2022 @RheumNow OP0255 Merola et al https://t.co/riU2sIXGs9
Dr. Antoni Chan synovialjoints ( View Tweet)
#LB0005 #EULAR2022 Phase 3 RCT of Bimekizumab, dual IL17A and 17F inhibitor in bDMARDs-naive PsA showed significant improvement in ACR50 and PASI90 scores vs Placebo. No major safety signals. Skin response is excellent! @RheumNow https://t.co/yhgB8LGXh6
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×